scispace - formally typeset
Journal ArticleDOI

Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting.

TLDR
From the intestinal lymphatic transport study it became evident that SLN increased the cumulative percentage dose of lopinavir secreted into the lymph, which was 4.91-fold higher when compared with a conventional drug solution in methyl cellulose 0.5% (w/v) as suspending agent (Lo-MC).
About
This article is published in European Journal of Pharmaceutical Sciences.The article was published on 2011-01-18. It has received 212 citations till now. The article focuses on the topics: Solid lipid nanoparticle & Glyceryl behenate.

read more

Citations
More filters
Journal ArticleDOI

Nanoparticles for oral delivery: Design, evaluation and state-of-the-art.

TL;DR: N nanoparticle design aspects to improve delivery to particular sites in the GI tract are discussed and the state-of-the-art in preclinical targeted nanoparticles design is reviewed.
Journal ArticleDOI

Solid lipid nanoparticles as attractive drug vehicles: Composition, properties and therapeutic strategies

TL;DR: This work briefly reviews up-to-date developments in solid lipid nanoparticles (SLNs) as effective nanocolloidal system for drug delivery and summarizes SLNs in terms of their preparation, surface modification and properties.
Journal ArticleDOI

Solid lipid nanoparticles: an oral bioavailability enhancer vehicle.

TL;DR: The protective effect of SLNs, coupled with their sustained/controlled release properties, prevents drugs/macromolecules from premature degradation and improves their stability in the GIT, and make SLNs a potential BA enhancer vehicle for various Class II, III and IV drugs.
Journal ArticleDOI

Lipid nanoparticles: Different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery

TL;DR: This review highlights the simple and easily scaled-up novel SLN and NLC along with their different production techniques, hurdles, and strategies for the production of LNs, characterization, lyophilization and drug release and summarizes the research findings reported by the different researchers regarding the different method of preparation, excipients and their significant findings.
Journal ArticleDOI

A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems

TL;DR: Although nano-structured lipid carriers and SLNs are based on lipids and surfactants, the effect of these two matrixes to build excipients is also discussed together with their pharmacological significance with novel theranostic approaches, stability and storage.
References
More filters
Journal ArticleDOI

Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals

TL;DR: In this study it has been proved that using SLN as a drug carrier for oral administration of cyclosporine A a low variation in bioavailability of the drug and simultaneously avoiding the plasma peak typical of the first Sandimmun formulation can be achieved.
Journal ArticleDOI

Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs.

TL;DR: Results indicate that ATRA absorption is enhanced significantly by employing SLN formulations, and SLNs offer a new approach to improve the oral bioavailability of poorly soluble drugs.
Journal ArticleDOI

Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery.

TL;DR: The comparative study conducted on methotrexate (MTX)-bearing SLNs revealed that the formulation based on Compritol 888 ATO could noticeably improve the oral bioavailability of MTX, presumably following SLNs constituting lipid digestion and co-absorption through lymphatic transport and route.
Journal ArticleDOI

Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses

TL;DR: It is suggested that a threshold of>50% CD4+ T-cell restoration may be sufficient for polyfunctional HIV-specific T cells with implications in the evaluation of vaccines and therapeutics.
Related Papers (5)